- Interactive Questions
- Online Chapter
- Further Reading
- Extracts from ELS
- Your feedback
- Become a reviewer
- More student books
- Student apps
- Join an e-mail list
Ancrile B.B., O’Hayer K.M., and Counter C.M. (2008) Oncogenic Ras‐induced expression of cytokines: a new target of anti‐cancer therapeutics. Molecular Interventions 8, 22–27.
Banchereau J. and Palucka A.K. (2005) Dendritic cells as therapeutic vaccines against cancer. Nature Reviews Immunology 5, 296–306.
Brown S.D., Warren R.L., Gibb E.A., et al. (2014) Neo‐antigens predicted by tumor genome meta‐analysis correlate with increased patient survival. Genome Research 24, 743–750.
Grivennikov S.I., Greten F.R., and Karin M. (2010) Immunity, inflammation, and cancer. Cell 140, 883–899.
Kahn J.A. (2009) HPV vaccination for the prevention of cervical intraepithelial neoplasia. New England Journal of Medicine 361, 271–278.
Karin M., Lawrence T., and Nizet V. (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823–835.
Loo D.T. and Mather JP. (2008) Antibody‐based identification of cell surface antigens: targets for cancer therapy. Current Opinion in Pharmacology 8, 627–631.
Mantovani A. and Allavena P. (2015) The interaction of anticancer therapies with tumor‐associated macrophages. Journal of Experimental Medicine 212, 435–445.
Melief C.J.M., van Hall T., Arens R., Ossendorp F., and van der Burg S.H. (2015) Therapeutic cancer vaccines. Journal of Clinical Investigation 125, 3401–3412.
Muranski P. and Restifo N.P. (2009) Adoptive immunotherapy of cancer using CD4+ T cells. Current Opinion in Immunology 21, 200–208.
Murphy A., Westwood J.A., Teng M.W., Moeller M., Darcy P.K., and Kershaw M.H. (2005) Gene modification strategies to induce tumor immunity. Immunity 22, 403–414.
Prendergast G.C., Smith C., Thomas S., et al. (2014) Indoleamine 2,3‐dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy 63, 721–735.
Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. (2007) Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 25, 267–296.
Ramos C.A., Heslop H.E., and Brenner M.K. (2016) CAR‐T cell therapy for lymphoma. Annual Review of Medicine 67, 165–183.
Reichert J.M. and Valge‐Archer, V.E. (2007) Development trends for monoclonal antibody cancer therapeutics. Nature Reviews Drug Discovery 6, 349–356.
Ruffell B. and Coussens L.M. (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462–472.
Sharma P. and Allison J.P. (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214.
Sliwkowski M.X. and Mellman I. (2013) Antibody therapeutics in cancer. Science 341, 1192–1198.
Srivastava P.K. (2015) Neoepitopes of cancers: looking back, looking ahead. Cancer Immunology Research 3, 969–977.
Taniguchi K. and Karin M. (2014) IL‐6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology 26, 54–74.
Teng M.W., Galon J., Fridman W.H., and Smyth M.J. (2015) From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation 125, 3338–3346.
Copyright © 2017 Peter J. Delves, Seamus J. Martin, Dennis R. Burton, Ivan M. Roitt